Publications by authors named "Katarzyna Borkowska"
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated.
View Article and Find Full Text PDFArticle Synopsis
- Novel therapies are changing how endometrial cancer (EC) is treated, with a systematic review assessing first-line treatments for advanced or recurrent cases.
- The review included 108 records from 57 trials, showing varied results with median progression-free survival between 1.9 to 18.8 months and overall survival from 6.9 to 41 months.
- Concerns about adverse events from conventional treatments suggest that while efficacy is suboptimal, the promising safety and effectiveness of immunotherapies could significantly alter EC management moving forward.
Article Synopsis
- Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is approved globally for treating adults with moderate to severe plaque psoriasis, especially those needing systemic therapy.
- A systematic review and meta-analysis analyzed its efficacy in Asian populations compared to other treatments, revealing significant improvement over placebo and apremilast.
- In Asian patients, deucravacitinib showed PASI 75 and 90 response rates that are comparable to several biologics, highlighting its effectiveness and convenience as an oral treatment option.
Introduction: The psychological burden of type 1 diabetes mellitus (T1DM) is considerable. The condition affects the daily lives of adults living with T1DM (ALWT1DM) in many ways. International guidelines highlight the importance of providing psychological support to ALWT1DM to improve health outcomes and well-being.
View Article and Find Full Text PDFAims: Acetylsalicylic acid (ASA) is widely used for the prevention of atherothrombotic events in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD), but the risk of vascular events remains high. We aimed at identifying randomised controlled trials (RCTs) on antithrombotic treatments in patients with chronic CAD or PAD.
Methods: Searches were conducted on MEDLINE, EMBASE, and CENTRAL on March 1, 2018.
Baloxavir marboxil (baloxavir) is the first cap-dependent endonuclease inhibitor being studied for the treatment of influenza in single oral dosing regimen. This network meta-analysis (NMA) evaluated the efficacy and safety of baloxavir compared to other antivirals for influenza in otherwise healthy patients. A systematic literature review was performed on 14 November 2016 in Medline, Embase, CENTRAL, and ICHUSHI to identify randomized controlled trials assessing antivirals for influenza.
View Article and Find Full Text PDF